Abstract
Aim:
Chondrosarcoma is a malignant primary bone tumor that responds poorly to both chemotherapy and radiation therapy. The aim of the present study was to investigate the effect of alendronate, a bisphosphonate, on the invasion and migration of human chondrosarcoma cells (JJ012).
Methods:
JJ012 cells were treated with alendronate of various concentrations up to 100 μmol/L for a specified period, and then gelatin zymography and matrigel invasion assay was performed to study the effects of alendronate on matrix metalloproteinase (MMP)-2 activity and the invasion ability of JJ012 cells, respectively.
Results:
Our data showed that alendronate exerted a dose- and time-dependent inhibitory effect on the invasion and migration of JJ012 cells. Furthermore, gelatin zymography and RT-PCR showed that alendronate treatment decreased the activity and mRNA levels of MMP-2 in a concentration-dependent manner.
Conclusion:
Our findings suggest that alendronate may reduce MMP-2 secretion at the transcriptional and translational levels, and inhibit the invasion of chondrosarcoma cell. Therefore, alendronate may be a potential candidate for the systemic therapy of chondro-sarcomas, as well as other malignant diseases.
Similar content being viewed by others
Article PDF
References
Terek RM, Schwartz GK, Devaney K, Glantz L, Mak S, Healey JH, et al. Chemotherapy and P-glycoprotein expression in chondrosarcoma. J Orthop Res 1998; 16: 585–90.
Yuan J, Dutton CM, Scully SP . RNAi mediated MMP-1 silencing inhibits human chondrosarcoma invasion. J Orthop Res 2005; 23: 1467–74.
Berend KR, Toth AP, Harrelson JM, Layfield LJ, Hey LA, Scully SP . Association between ratio of matrix metalloproteinase-1 to tissue inhibitor of metalloproteinase-1 and local recurrence, metastasis, and survival in human chondrosarcoma. J Bone Joint Surg Am 1998; 80: 11–7.
Kawata R, Shimada T, Maruyama S, Hisa Y, Takenaka H, Murakami Y . Enhanced production of matrix metalloproteinase-2 in human head and neck carcinomas is correlated with lymph node metastasis. Acta Otolaryngol 2002; 122: 101–6.
Pei Y, Harvey A, Yu XP, Chandrasekhar S, Thirunavukkarasu K . Differential regulation of cytokine-induced MMP-1 and MMP-13 expression by p38 kinase inhibitors in human chondrosarcoma cells: potential role of Runx2 in mediating p38 effects. Osteoarthritis Cartilage 2006; 14: 749–58.
Fong YC, Dutton CM, Cha SS, Garamszegi N, Sim FH, Scully SP . Absence of a correlation between the presence of a single nucleotide polymorphism in the matrix metalloproteinase 1 promoter and outcome in patients of chondrosarcoma. Clin Cancer Res 2004; 10: 7329–34.
Yoon SO, Park SJ, Yun CH, Chung AS . Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol 2003; 36: 128–37.
Yang SF, Hsieh YS, Lin CL, Hsu NY, Chiou HL, Chou FP, et al. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients. Clin Chim Acta 2005; 354: 91–9.
Bjorklund M, Koivunen E . Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 2005; 1755: 37–69.
Clezardin P . Anti-tumour activity of zoledronic acid. Cancer Treat Rev 2005; 31: 1–8.
Muller S, Migianu E, Lecouvey M, Kraemer M, Oudar O . Alendronate inhibits proliferation and invasion of human epidermoid carcinoma cells in vitro. Anticancer Res 2005; 25: 2655–60.
Cheng YY, Huang L, Lee KM, Li K, Kumta SM . Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines. Pediatr Blood Cancer 2004; 42: 410–5.
Forsea AM, Muller C, Riebeling C, Orfanos CE, Geilen CC . Nitrogen-containing bisphosphonates inhibit cell cycle progression in human melanoma cells. Br J Cancer 2004; 91: 803–10.
Fromigue O, Lagneaux L, Body JJ . Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000; 15: 2211–21.
Heikkila P, Teronen O, Moilanen M, Konttinen YT, Hanemaaijer R, Laitinen M, et al. Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Anticancer Drugs 2002; 13: 245–54.
Lee MV, Fong EM, Singer FR, Guenette RS . Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001; 61: 2602–8.
Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW . Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000; 82: 1459–68.
Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W, van Valen F . The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs 2001; 12: 459–65.
Virtanen SS, Vaananen HK, Harkonen PL, Lakkakorpi PT . Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 2002; 62: 2708–14.
Block JA, Inerot SE, Gitelis S, Kimura JH . Synthesis of chondrocytic keratan sulphate-containing proteoglycans by human chondrosarcoma cells in long-term cell culture. J Bone Joint Surg Am 1991; 73: 647–58.
Mosmann T . Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55–63.
Yang SF, Chu SC, Chiang IC, Kuo WF, Chiou HL, Chou FP, et al. Excessive matrix metalloproteinase-9 in the plasma of community-acquired pneumonia. Clin Chim Acta 2005; 352: 209–15.
Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J . Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000; 88: 2961–78.
Clezardin P . The antitumor potential of bisphosphonates. Semin Oncol 2002; 29: 33–42.
Green JR . Antitumor effects of bisphosphonates. Cancer 2003; 97: 840–7.
Heymann D, Ory B, Gouin F, Green JR, Redini F . Bisphosphonates: new therapeutic agents for the treatment of bone tumors. Trends Mol Med 2004; 10: 337–43.
Diel IJ . Antitumour effects of bisphosphonates: first evidence and possible mechanisms. Drugs 2000; 59: 391–9.
Lauer JL, Furcht LT, Fields GB . Inhibition of melanoma cell binding to type IV collagen by analogs of cell adhesion regulator. J Med Chem 1997; 40: 3077–84.
Author information
Authors and Affiliations
Corresponding author
Additional information
This study was supported by grants from China Medical University (No CMU-93-CM-15 and CMU-94-015) and China Medical University Hospital (No DMR-94-036 and DMR-95-067).
Rights and permissions
About this article
Cite this article
Lai, Tj., Hsu, Sf., Li, Tm. et al. Alendronate inhibits cell invasion and MMP-2 secretion in human chondrosarcoma cell line. Acta Pharmacol Sin 28, 1231–1235 (2007). https://doi.org/10.1111/j.1745-7254.2007.00607.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2007.00607.x
Keywords
This article is cited by
-
In vitro effects of alendronate on fibroblasts of the human rotator cuff tendon
BMC Musculoskeletal Disorders (2020)
-
Cartilage tumours and bone development: molecular pathology and possible therapeutic targets
Nature Reviews Cancer (2010)